GPX4 and non-small cell lung carcinoma: In NSCLC models, perturbing redox–ferroptosis defenses increases ferroptosis susceptibility (with links to GPX4 downregulation) [116], and, more broadly across drug-resistant solid tumors, inhibition of the System Xc−/GSH/GPX4 axis restores ferroptosis sensitivity [117].